DE2010416B2 - Oral anwendbare Arzneiform mit Retardwirkung - Google Patents

Oral anwendbare Arzneiform mit Retardwirkung

Info

Publication number
DE2010416B2
DE2010416B2 DE2010416A DE2010416A DE2010416B2 DE 2010416 B2 DE2010416 B2 DE 2010416B2 DE 2010416 A DE2010416 A DE 2010416A DE 2010416 A DE2010416 A DE 2010416A DE 2010416 B2 DE2010416 B2 DE 2010416B2
Authority
DE
Germany
Prior art keywords
active ingredient
beads
coating
sustained release
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
DE2010416A
Other languages
German (de)
English (en)
Other versions
DE2010416A1 (de
Inventor
Werner Dr. 6233 Kelkheim Fuelberth
Erika 6230 Frankfurt Neitzer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Priority to DE2010416A priority Critical patent/DE2010416B2/de
Priority to CA105,675A priority patent/CA977680A/en
Priority to NLAANVRAGE7102590,A priority patent/NL169680C/xx
Priority to ES388698A priority patent/ES388698A1/es
Priority to BE763735A priority patent/BE763735A/xx
Priority to FR7107439A priority patent/FR2085672B1/fr
Priority to DK101271A priority patent/DK132303C/da
Priority to ZA711412A priority patent/ZA711412B/xx
Priority to US00121173A priority patent/US3835221A/en
Priority to SE7102757A priority patent/SE377886B/xx
Priority to AT187171A priority patent/AT305498B/de
Priority to JP1176771A priority patent/JPS5331930B1/ja
Priority to GB2323171*A priority patent/GB1326995A/en
Publication of DE2010416A1 publication Critical patent/DE2010416A1/de
Publication of DE2010416B2 publication Critical patent/DE2010416B2/de
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
DE2010416A 1970-03-05 1970-03-05 Oral anwendbare Arzneiform mit Retardwirkung Ceased DE2010416B2 (de)

Priority Applications (13)

Application Number Priority Date Filing Date Title
DE2010416A DE2010416B2 (de) 1970-03-05 1970-03-05 Oral anwendbare Arzneiform mit Retardwirkung
CA105,675A CA977680A (en) 1970-03-05 1971-02-18 Orally administrable drug dosage form with delayed release
NLAANVRAGE7102590,A NL169680C (nl) 1970-03-05 1971-02-26 Werkwijze voor het bereiden van omhulde, oraal toe te dienen geneesmiddelen met verlengde werking.
ES388698A ES388698A1 (es) 1970-03-05 1971-02-27 Procedimiento para la preparacion de pequenas bolitas medi-camentosas para administracion oral con un revestimiento re-tardador de la liberacion de sustancia activa.
BE763735A BE763735A (fr) 1970-03-05 1971-03-03 Forme pharmaceutique a effet retard et sa
FR7107439A FR2085672B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1970-03-05 1971-03-04
DK101271A DK132303C (da) 1970-03-05 1971-03-04 Fremgangsmade til fremstilling af en legemiddelform med retarderende virkning
ZA711412A ZA711412B (en) 1970-03-05 1971-03-04 Orally administrable drug dosage form having delayed action
US00121173A US3835221A (en) 1970-03-05 1971-03-04 Orally administrable drug dosage form having delayed action
SE7102757A SE377886B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1970-03-05 1971-03-04
AT187171A AT305498B (de) 1970-03-05 1971-03-04 Verfahren zur Herstellung einer oral zu verabreichenden Arzneiform mit Retardwirkung
JP1176771A JPS5331930B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1970-03-05 1971-03-05
GB2323171*A GB1326995A (en) 1970-03-05 1971-04-19 Orally administrable drug dosage form having delayed action

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2010416A DE2010416B2 (de) 1970-03-05 1970-03-05 Oral anwendbare Arzneiform mit Retardwirkung

Publications (2)

Publication Number Publication Date
DE2010416A1 DE2010416A1 (de) 1971-09-16
DE2010416B2 true DE2010416B2 (de) 1979-03-29

Family

ID=5764197

Family Applications (1)

Application Number Title Priority Date Filing Date
DE2010416A Ceased DE2010416B2 (de) 1970-03-05 1970-03-05 Oral anwendbare Arzneiform mit Retardwirkung

Country Status (13)

Country Link
US (1) US3835221A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPS5331930B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) AT305498B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE763735A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA977680A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE2010416B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK132303C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES388698A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR2085672B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (1) GB1326995A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL169680C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SE (1) SE377886B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA711412B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1468172A (en) * 1973-03-28 1977-03-23 Benzon As Alfred Oral drug preparations
DE2336218C3 (de) * 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
DE2343218C2 (de) * 1973-08-28 1986-08-07 Hoechst Ag, 6230 Frankfurt Furosemid enthaltende Pellets
FR2377196A1 (fr) * 1977-01-13 1978-08-11 Lipha Composition medicamenteuse a usage oral
GB1561204A (en) * 1977-06-01 1980-02-13 Ici Ltd Sustained release pharmaceutical composition
FR2397840B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1977-07-22 1981-03-20 Cherqui Jean
US4153677A (en) * 1978-05-18 1979-05-08 Sterling Drug Inc. Controlled-release composition
GB1584130A (en) * 1978-05-30 1981-02-04 Wyeth John & Brother Ltd Indole derivatives
DD146547A5 (de) * 1978-07-15 1981-02-18 Boehringer Sohn Ingelheim Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen
SE426548B (sv) * 1978-12-05 1983-01-31 Haessle Ab Fast farmaceutisk beredning innehallande en terapeutiskt effektiv hjertglykosid och en polymer
US4173626A (en) * 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
SE7813246L (sv) * 1978-12-22 1980-06-23 Haessle Ab Fast farmaceutisk beredning innehallande kroppar med flera ytskikt
JPS55129219A (en) * 1979-03-29 1980-10-06 Asahi Chem Ind Co Ltd Slow-releasing preparation
FR2454804B1 (fr) * 1979-04-26 1986-11-21 Sanofi Sa Medicament a base de dihydroergotoxine et son procede de preparation
US4252786A (en) * 1979-11-16 1981-02-24 E. R. Squibb & Sons, Inc. Controlled release tablet
US4543370A (en) * 1979-11-29 1985-09-24 Colorcon, Inc. Dry edible film coating composition, method and coating form
FR2470599A1 (fr) * 1979-12-07 1981-06-12 Panoz Donald Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
DE3000979A1 (de) * 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
SE8103843L (sv) * 1981-06-18 1982-12-19 Astra Laekemedel Ab Farmaceutisk mixtur
DE3126703A1 (de) 1981-07-07 1983-01-27 Dr. Karl Thomae Gmbh, 7950 Biberach Bromhexin-retardform und verfahren zu ihrer herstellung
DE3278491D1 (en) * 1981-07-15 1988-06-23 Key Pharma Sustained release theophyline
US4587118A (en) * 1981-07-15 1986-05-06 Key Pharmaceuticals, Inc. Dry sustained release theophylline oral formulation
US4415547A (en) * 1982-06-14 1983-11-15 Sterling Drug Inc. Sustained-release pharmaceutical tablet and process for preparation thereof
US4508702A (en) * 1982-06-14 1985-04-02 Key Pharmaceuticals, Inc. Sustained release aspirin
WO1984000004A1 (en) * 1982-06-14 1984-01-05 Key Pharma Sustained release aspirin
US4557925A (en) * 1982-07-08 1985-12-10 Ab Ferrosan Membrane-coated sustained-release tablets and method
WO1984000295A1 (en) * 1982-07-09 1984-02-02 Key Pharma Sustained release quinidine dosage form
US4634587A (en) * 1982-07-09 1987-01-06 Key Pharmaceuticals, Inc. Sustained release quinidine dosage form
IE55745B1 (en) * 1983-04-06 1991-01-02 Elan Corp Plc Sustained absorption pharmaceutical composition
USRE33994E (en) * 1983-08-16 1992-07-14 Burroughs Wellcome Co. Pharmaceutical delivery system
GB8322007D0 (en) * 1983-08-16 1983-09-21 Wellcome Found Pharmaceutical delivery system
JPS6051106A (ja) * 1983-08-31 1985-03-22 Yamanouchi Pharmaceut Co Ltd 塩酸アモスラロ−ル持続性製剤
US4749575A (en) * 1983-10-03 1988-06-07 Bio-Dar Ltd. Microencapsulated medicament in sweet matrix
US4555399A (en) * 1983-11-18 1985-11-26 Key Pharmaceuticals, Inc. Aspirin tablet
DE3403329A1 (de) * 1984-02-01 1985-08-01 Horst Dr. 4019 Monheim Zerbe Pharmazeutisches produkt in form von pellets mit kontinuierlicher, verzoegerter wirkstoffabgabe
GB8414221D0 (en) * 1984-06-04 1984-07-11 Sterwin Ag Unit dosage form
GB2159714B (en) * 1984-06-04 1988-05-05 Sterwin Ag Pharmaceutical composition of sparingly soluble medicament and method for its preparation
US4769027A (en) * 1984-08-15 1988-09-06 Burroughs Wellcome Co. Delivery system
EP0467488B1 (en) * 1984-08-17 1995-10-11 The Wellcome Foundation Limited Composition for the controlled discharge of an active ingredient
US4629619A (en) * 1984-09-05 1986-12-16 Ab Ferrosan Membrane-coated sustained-release tablets and method
US4629620A (en) * 1984-09-05 1986-12-16 Ab Ferrosan Membrane-coated sustained-release tablets and method
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4867984A (en) * 1984-11-06 1989-09-19 Nagin K. Patel Drug in bead form and process for preparing same
CA1268710A (en) * 1984-11-06 1990-05-08 Nagin K. Patel Drug in bead form and process for preparing same
US4728512A (en) * 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
US4666704A (en) * 1985-05-24 1987-05-19 International Minerals & Chemical Corp. Controlled release delivery system for macromolecules
US4794001A (en) * 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
US4904476A (en) * 1986-03-04 1990-02-27 American Home Products Corporation Formulations providing three distinct releases
US5286494A (en) * 1986-07-02 1994-02-15 Schering Aktiengesellschaft Medicinal agents with sustained action
JPS6327424A (ja) * 1986-07-17 1988-02-05 Shionogi & Co Ltd 徐放性製剤およびその製造法
US4752470A (en) * 1986-11-24 1988-06-21 Mehta Atul M Controlled release indomethacin
US4786509A (en) * 1987-05-18 1988-11-22 Schering Corporation Dry sustained release theophylline oral formulation
US5122384A (en) * 1989-05-05 1992-06-16 Kv Pharmaceutical Company Oral once-per-day organic nitrate formulation which does not induce tolerance
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5084287A (en) * 1990-03-15 1992-01-28 Warner-Lambert Company Pharmaceutically useful micropellets with a drug-coated core and controlled-release polymeric coat
US5707652A (en) * 1990-12-04 1998-01-13 State Of Oregon Methods of treating circadian rhythm phase disorders
US6638963B1 (en) 1990-12-04 2003-10-28 Oregon Health And Science University Methods for treating circadian rhythm disorders
US5252337A (en) * 1991-06-25 1993-10-12 Eurand America, Inc. Controlled release calcium channel blocker microcapsules
IL110035A0 (en) * 1994-06-16 1994-10-07 Tapuach Natural Technologies 1 Homeopathic formulations
US5744164A (en) * 1994-12-16 1998-04-28 Nestec S.A. Sustained release microparticulate caffeine formulation
US5834024A (en) * 1995-01-05 1998-11-10 Fh Faulding & Co. Limited Controlled absorption diltiazem pharmaceutical formulation
US6270795B1 (en) 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
US20020182258A1 (en) * 1997-01-22 2002-12-05 Zycos Inc., A Delaware Corporation Microparticles for delivery of nucleic acid
FR2766367B1 (fr) * 1997-07-22 2000-03-31 Plantes Et Medecines Granules homeopathiques et procede de fabrication
DE19732903A1 (de) 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
UA69413C2 (uk) * 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
US6432448B1 (en) 1999-02-08 2002-08-13 Fmc Corporation Edible coating composition
US6723342B1 (en) 1999-02-08 2004-04-20 Fmc Corporation Edible coating composition
US20050037086A1 (en) * 1999-11-19 2005-02-17 Zycos Inc., A Delaware Corporation Continuous-flow method for preparing microparticles
US20040185099A1 (en) * 2000-01-20 2004-09-23 Biovail Laboratories, Inc. Multiparticulate bisoprolol formulation
US6254888B1 (en) 2000-01-28 2001-07-03 Boehringer Ingelheim Pharmaceuticals, Inc. Method for coating pharmaceutical dosage forms
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6635277B2 (en) 2000-04-12 2003-10-21 Wockhardt Limited Composition for pulsatile delivery of diltiazem and process of manufacture
JP2003535122A (ja) * 2000-06-02 2003-11-25 ザイコス インク． 生物活性物質のための送達システム
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6932861B2 (en) 2000-11-28 2005-08-23 Fmc Corporation Edible PGA coating composition
BR0115585A (pt) 2000-11-28 2005-12-13 Fmc Corp Composições de revestimento de pronta liberação, endurecìvel, comestìvel, seca e, úmida, forma de dosagem sólida, e, método para revestir uma forma de dosagem sólida farmacêutica ou veterinária, confeito, semente, ração animal, fertilizante, comprimido de pesticida ou alimento
US20040234602A1 (en) 2001-09-21 2004-11-25 Gina Fischer Polymer release system
EP1429744A1 (en) 2001-09-21 2004-06-23 Egalet A/S Morphine polymer release system
AU2003225102A1 (en) * 2002-04-23 2003-11-10 Bristol-Myers Squibb Company Modified-release vasopeptidase inhibitor formulation, combinations and method
US20040029959A1 (en) * 2002-08-08 2004-02-12 John Devane Isosorbide mononitrate compositions and methods of their use
WO2004084868A1 (en) 2003-03-26 2004-10-07 Egalet A/S Morphine controlled release system
US20090274759A1 (en) * 2005-06-03 2009-11-05 Egalet A/S Solid pharmaceutical composition with a first fraction of a dispersion medium and a second fraction of a matrix, the latter being at least partially first exposed to gastrointestinal fluids
MX2008009647A (es) 2006-01-27 2008-09-25 Univ California Cisteamina recubierta entéricamente, cistamina y derivados de ella.
CA2930487A1 (en) * 2007-01-16 2008-07-24 Egalet Ltd. Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i)mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
WO2008148798A2 (en) 2007-06-04 2008-12-11 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
JP5548675B2 (ja) 2008-04-24 2014-07-16 ブリストル−マイヤーズ スクイブ カンパニー アルツハイマー病を含めたタウ関連疾患の治療におけるエポチロンｄの使用
WO2010089132A1 (en) 2009-02-06 2010-08-12 Egalet A/S Immediate release composition resistant to abuse by intake of alcohol
NZ603579A (en) 2009-06-24 2014-02-28 Egalet Ltd Controlled release formulations
WO2012100208A1 (en) 2011-01-20 2012-07-26 Bionevia Pharmaceuticals Inc. Modified release compositions of epalrestat or a derivative thereof and methods for using the same
JP6411215B2 (ja) 2011-11-22 2018-10-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 虚血傷害を治療するためのシステアミンおよび／またはシスタミン
JP6189945B2 (ja) 2012-06-18 2017-08-30 プリンシピア バイオファーマ インコーポレイテッド 癌および自己免疫疾患の治療に有用な可逆性共有結合ピロロ−またはピラゾロピリミジン
WO2014004707A1 (en) 2012-06-29 2014-01-03 Principia Biopharma Inc. Formulations comprising ibrutinib
CN104684548A (zh) 2012-07-06 2015-06-03 埃格勒特有限责任公司 防止滥用的控释药物组合物
AR096628A1 (es) 2013-06-17 2016-01-20 Raptor Pharmaceuticals Inc Formulación en perlas de cisteamina de liberación retardada y métodos de preparación y uso de ella
MX378435B (es) 2014-12-24 2025-03-11 Principia Biopharma Inc Administración específica del sitio de un inhibidor de btk.
UA124090C2 (uk) 2015-06-03 2021-07-21 Прінсіпіа Байофарма Інк. Інгібітори тирозинкінази
WO2016210165A1 (en) 2015-06-24 2016-12-29 Principia Biopharma Inc. Tyrosine kinase inhibitors
TWI759267B (zh) 2015-07-02 2022-04-01 美商地平線罕見醫學製藥有限責任公司 Ａｄｏ抗性半胱胺類似物及其用途
US10143665B2 (en) 2015-11-17 2018-12-04 Horizon Orphan Llc Methods for storing cysteamine formulations and related methods of treatment
CN108289848A (zh) * 2015-12-08 2018-07-17 阿迪亚生命科学公司 包含urat1的有效抑制剂的药物组合物
SG11201811255WA (en) 2016-06-29 2019-01-30 Principia Biopharma Inc Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
JP2023510604A (ja) 2020-01-20 2023-03-14 ジェンザイム・コーポレーション 再発型多発性硬化症（ｒｍｓ）用の治療用チロシンキナーゼ阻害剤
CA3173330A1 (en) 2020-04-17 2021-10-21 Genzyme Corporation Eclitasertib for use in treating conditions involving systemichyperinflammatory response
WO2022178214A1 (en) 2021-02-19 2022-08-25 Dupont Nutrition Biosciences Aps Compositions for gut health
WO2022181625A1 (en) 2021-02-23 2022-09-01 Otsuka Pharmaceutical Co., Ltd. Centanafadine pharmaceutical formulations, and methods of making and using same
TW202421141A (zh) 2022-06-30 2024-06-01 美商健臻公司 用於多發性硬化症及重症肌無力之治療性酪胺酸激酶抑制劑
CN120202294A (zh) 2022-08-16 2025-06-24 国际N&H丹麦有限公司 磷酸酶表达系统
CN119730840A (zh) 2022-09-02 2025-03-28 大塚制药株式会社 用于治疗重度抑郁症的1-(萘-2-基)-3-氮杂双环[3.1.0]己烷
WO2024064653A1 (en) 2022-09-20 2024-03-28 Dupont Nutrition Biosciences Aps Variant anti-viral polypeptides
TW202430175A (zh) 2022-10-11 2024-08-01 美商健臻公司 用於多發性硬化症的治療性酪胺酸激酶抑制劑
WO2025064636A1 (en) 2023-09-20 2025-03-27 Danisco Us Inc. Composition comprising an atp degrading enzyme and uses thereof
WO2025080755A1 (en) 2023-10-13 2025-04-17 Nutrition & Biosciences USA 4, Inc. Methods and compositions for aging and mitochondrial health

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2410417A (en) * 1944-03-04 1946-11-05 Lever Brothers Ltd Vitamin and mineral dietary supplement and method of making
CH283585A (de) * 1950-03-15 1952-06-15 Hoffmann La Roche Zur Herstellung von Tablettenüberzügen geeignetes Gemisch.
FR1017117A (fr) * 1950-05-04 1952-12-02 Trialgol Lab Procédé de conditionnement à l'état de poudre de substances destinées à l'ingestion et produits en résultant
US2996431A (en) * 1953-12-16 1961-08-15 Barry Richard Henry Friable tablet and process for manufacturing same
US2811483A (en) * 1954-12-09 1957-10-29 Pfizer & Co C Pharmaceutical composition and process for preparing the same
US2853420A (en) * 1956-01-25 1958-09-23 Lowey Hans Ethyl cellulose coatings for shaped medicinal preparations
US2852433A (en) * 1956-03-07 1958-09-16 Eastman Kodak Co Method of making enteric medicament compositions
US2928770A (en) * 1958-11-28 1960-03-15 Frank M Bardani Sustained action pill
US3096248A (en) * 1959-04-06 1963-07-02 Rexall Drug & Chemical Company Method of making an encapsulated tablet
DE1228757B (de) * 1962-06-28 1966-11-17 Haessle Ab Verfahren zur Herstellung eines in Wasser und Magensaft rasch zerfallenden UEberzuges auf festen Arzneiformen
US3247066A (en) * 1962-09-12 1966-04-19 Parke Davis & Co Controlled release dosage form containing water-swellable beadlet
US3325365A (en) * 1963-04-02 1967-06-13 Ciba Geigy Corp Enteric composition for tablet compression coating
DE1216486B (de) * 1964-04-23 1966-05-12 Merck Ag E Verfahren zur Herstellung von Dragees
US3365365A (en) * 1965-08-09 1968-01-23 Hoffmann La Roche Repeat action pharmaceutical compositions in the form of discrete beadlets
US3538214A (en) * 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets

Also Published As

Publication number Publication date
DK132303B (da) 1975-11-24
ES388698A1 (es) 1974-02-16
GB1326995A (en) 1973-08-15
US3835221A (en) 1974-09-10
JPS5331930B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1978-09-05
NL169680C (nl) 1982-08-16
FR2085672B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1974-04-12
ZA711412B (en) 1971-11-24
FR2085672A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1971-12-31
AT305498B (de) 1973-02-26
NL169680B (nl) 1982-03-16
CA977680A (en) 1975-11-11
NL7102590A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1971-09-07
SE377886B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1975-08-04
DE2010416A1 (de) 1971-09-16
BE763735A (fr) 1971-09-03
DK132303C (da) 1976-04-26

Similar Documents

Publication Publication Date Title
DE2010416B2 (de) Oral anwendbare Arzneiform mit Retardwirkung
DE69825165T2 (de) Arzneimittelform mit zwei überzugs-schichten
DE2336218C3 (de) Orale Arzneiform
DE2414868C3 (de) Teilchenförmige Arzneimittel
DE69331906T2 (de) Granulierte pharmazeutische zusammensetzung
DE2636152C2 (de) Verfahren zur Herstellung von Dragees
AT396329B (de) Pharmazeutische granulate und verfahren zu ihrer herstellung
EP0032562B1 (de) Neue Dipyridamol-Retardformen und Verfahren zu ihrer Herstellung
DE3486409T2 (de) Zusammensetzung zur kontrollierten Abgabe eines Wirkstoffs.
DE2950977C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP0069259B1 (de) Bromhexin-Retardform und Verfahren zu ihrer Herstellung
DE1467961A1 (de) Medikamententraegerstoffe mit Freigabeverzoegerung und Verfahren zu ihrer Herstellung
DE1617724A1 (de) Verfahren zur Herstellung von Arzneimitteln mit verzoegerter Wirkung
WO2001035934A1 (de) Filmförmige zubereitung zur biphasigen freisetzung pharmakologisch wirksamer oder anderer substanzen
DE1492107A1 (de) Verfahren zur Herstellung einer Tablette
DE2246037A1 (de) Peroral anwendbares arzneimittel mit verstaerkter resorptionsverzoegerung
DE68907177T2 (de) Dosierungsform.
DE2741755C2 (de) Überzugsmassen auf Polymerbasis für biologisch aktive Präparate, Verfahren zu ihrer Herstellung sowie mit diesen Überzugsmassen überzogene biologisch aktive Präparate und Verfahren zur Herstellung derselben
DE1617784A1 (de) Neue Arzneimittelform und ihre Herstellung
DE2223896A1 (de) Verfahren zum ueberziehen von feinteiligen arzneimitteln
DE1617522A1 (de) Verfahren zur Herstellung einer Arzneimittelzubereitung
DE69104836T2 (de) Mit gelatine überzogene arzneimittel sowie verfahren zu deren herstellung.
DE2105110A1 (de) Neuartiges Medikament
EP0271438B1 (de) Orales osmotisches System für Metoprolol mit verbesserten Formulierungseigenschaften
AT267069B (de) Verfahren zur Herstellung einer Arzneimittelzubereitung

Legal Events

Date Code Title Description
8235 Patent refused